Corton Capital Inc. Sells 9,075 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Corton Capital Inc. reduced its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 61.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,759 shares of the company's stock after selling 9,075 shares during the quarter. Corton Capital Inc.'s holdings in Scholar Rock were worth $249,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SRRK. GAMMA Investing LLC grew its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after buying an additional 379 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after acquiring an additional 620 shares during the period. Global Retirement Partners LLC raised its stake in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares during the period. Finally, Nisa Investment Advisors LLC boosted its position in Scholar Rock by 1,321.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the period. Institutional investors and hedge funds own 91.08% of the company's stock.

Insider Buying and Selling at Scholar Rock

In related news, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares of the company's stock, valued at approximately $4,154,541.60. The trade was a 38.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the transaction, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. The trade was a 56.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 255,231 shares of company stock valued at $9,220,236. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Price Performance

Shares of Scholar Rock stock traded down $0.14 on Friday, reaching $30.85. 846,155 shares of the stock were exchanged, compared to its average volume of 1,268,790. The firm's 50 day moving average is $31.63 and its 200-day moving average is $35.87. The firm has a market cap of $2.93 billion, a PE ratio of -13.13 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.